Company profile GLSI
There is not enough data for greenwich lifesciences clinical trial to provide analysis
There is not enough data for greenwich lifesciences clinical trial to provide correlation calculation
There is not enough data for greenwich lifesciences clinical trial to provide analysis
After 39 days of this quarter the interest is at 63.0. Based on that we can calculate that during remaining 52 days it will total up to 147.0. gp2 immunotherapy expected interest is significantly higher compared to previous quarter (+226.7%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 121 | 228 88.4% QoQ | 117 -48.7% QoQ | 148 26.5% QoQ |
| 2020 | 177 46.3% YoY 19.6% QoQ | 111 -51.3% YoY -37.3% QoQ | 41 -65.0% YoY -63.1% QoQ | 115 -22.3% YoY 180.5% QoQ |
| 2021 | 92 -48.0% YoY -20.0% QoQ | 64 -42.3% YoY -30.4% QoQ | 0 -100.0% YoY -100.0% QoQ | 250 117.4% YoY inf% QoQ |
| 2022 | 67 -27.2% YoY -73.2% QoQ | 0 -100.0% YoY -100.0% QoQ | 138 inf% YoY inf% QoQ | 82 -67.2% YoY -40.6% QoQ |
| 2023 | 117 74.6% YoY 42.7% QoQ | 193 inf% YoY 65.0% QoQ | 63 -54.3% YoY -67.4% QoQ | 45 -45.1% YoY -28.6% QoQ |
| 2024 | 63 -46.2% YoY 40.0% QoQ | - | - | - |
The average 5 years interest of gp2 immunotherapy was 8.55 per week. The last year interest of gp2 immunotherapy compared to the last 5 years has changed by 0.58%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -27.18%.
After 39 days of this quarter the interest is at 131.0. Based on that we can calculate that during remaining 52 days it will total up to 306.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 382 | 414 8.4% QoQ | 407 -1.7% QoQ | 550 35.1% QoQ |
| 2020 | 425 11.3% YoY -22.7% QoQ | 362 -12.6% YoY -14.8% QoQ | 309 -24.1% YoY -14.6% QoQ | 428 -22.2% YoY 38.5% QoQ |
| 2021 | 442 4.0% YoY 3.3% QoQ | 341 -5.8% YoY -22.9% QoQ | 342 10.7% YoY 0.3% QoQ | 386 -9.8% YoY 12.9% QoQ |
| 2022 | 409 -7.5% YoY 6.0% QoQ | 601 76.2% YoY 46.9% QoQ | 384 12.3% YoY -36.1% QoQ | 387 0.3% YoY 0.8% QoQ |
| 2023 | 443 8.3% YoY 14.5% QoQ | 447 -25.6% YoY 0.9% QoQ | 471 22.7% YoY 5.4% QoQ | 509 31.5% YoY 8.1% QoQ |
| 2024 | 131 -70.4% YoY -74.3% QoQ | - | - | - |
The average 5 years interest of breast cancer immunotherapy was 32.84 per week. The last year interest of breast cancer immunotherapy compared to the last 5 years has changed by 3.93%. The interest for breast cancer immunotherapy is seasonal. The last year interest is comparable to 5 years ago. It has changed only by -9.4%.
There is not enough data for her2/neu expressing cancers to provide analysis
There is not enough data for her2/neu expressing cancers to provide correlation calculation
There is not enough data for her2/neu expressing cancers to provide analysis
There is not enough data for greenwich lifesciences location to provide analysis
There is not enough data for greenwich lifesciences location to provide correlation calculation
There is not enough data for greenwich lifesciences location to provide analysis
After 39 days of this quarter the interest is at 23.0. Based on that we can calculate that during remaining 52 days it will total up to 54.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 18 inf% QoQ | 0 -100.0% QoQ | 13 inf% QoQ |
| 2020 | 48 inf% YoY 269.2% QoQ | 26 44.4% YoY -45.8% QoQ | 0 44.4% YoY -100.0% QoQ | 224 1623.1% YoY inf% QoQ |
| 2021 | 22 -54.2% YoY -90.2% QoQ | 76 192.3% YoY 245.5% QoQ | 28 inf% YoY -63.2% QoQ | 72 -67.9% YoY 157.1% QoQ |
| 2022 | 31 40.9% YoY -56.9% QoQ | 157 106.6% YoY 406.5% QoQ | 0 -100.0% YoY -100.0% QoQ | 31 -56.9% YoY inf% QoQ |
| 2023 | 84 171.0% YoY 171.0% QoQ | 103 -34.4% YoY 22.6% QoQ | 0 -34.4% YoY -100.0% QoQ | 41 32.3% YoY inf% QoQ |
| 2024 | 23 -72.6% YoY -43.9% QoQ | - | - | - |
The average 5 years interest of greenwich lifesciences stock price was 3.82 per week. The last year interest of greenwich lifesciences stock price compared to the last 5 years has changed by 2.62%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 300.0%.
After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0. greenwich lifesciences news expected interest is significantly lower compared to same quarter last year (-100.0%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 132 inf% QoQ | 205 55.3% QoQ | 103 -49.8% QoQ |
| 2020 | 115 inf% YoY 11.7% QoQ | 0 -100.0% YoY -100.0% QoQ | 43 -79.0% YoY inf% QoQ | 196 90.3% YoY 355.8% QoQ |
| 2021 | 164 42.6% YoY -16.3% QoQ | 35 inf% YoY -78.7% QoQ | 0 -100.0% YoY -100.0% QoQ | 200 2.0% YoY inf% QoQ |
| 2022 | 0 -100.0% YoY -100.0% QoQ | 49 40.0% YoY inf% QoQ | 18 inf% YoY -63.3% QoQ | 38 -81.0% YoY 111.1% QoQ |
| 2023 | 67 inf% YoY 76.3% QoQ | 86 75.5% YoY 28.4% QoQ | 56 211.1% YoY -34.9% QoQ | 0 -100.0% YoY -100.0% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of greenwich lifesciences news was 5.77 per week. The last year interest of greenwich lifesciences news compared to the last 5 years has changed by -35.36%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -61.43%.
There is not enough data for greenwich lifesciences website to provide analysis
There is not enough data for greenwich lifesciences website to provide correlation calculation
There is not enough data for greenwich lifesciences website to provide analysis
There is not enough data for snehal patel ceo to provide analysis
There is not enough data for snehal patel ceo to provide correlation calculation
There is not enough data for snehal patel ceo to provide analysis
There is not enough data for eric rothe independent director to provide analysis
There is not enough data for eric rothe independent director to provide correlation calculation
There is not enough data for eric rothe independent director to provide analysis